{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-100256","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2023-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.142450+00:00","generated_at":"2026-06-10T19:14:50.103938+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"HOOKIPA CMO Schlienger resigns; Board member Dr. Peters named interim clinical lead","bullets":["CMO Dr. Katia Schlienger resigns effective September 30, 2023 to pursue new opportunities.","Board member Dr. Malte Peters, former MorphoSys R&D head, appointed Senior Clinical Advisor ad interim.","CEO reaffirms focus on HB-200 randomized trial, HB-300 prostate program, and Roche/Gilead collaborations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-100256","json":"https://secwatch.observer/filing/0001104659-23-100256.json","markdown":"https://secwatch.observer/filing/0001104659-23-100256.md","text":"https://secwatch.observer/filing/0001104659-23-100256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000110465923100256/0001104659-23-100256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000110465923100256/tm2325987d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T19:14:50.103938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}